Your browser doesn't support javascript.
loading
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity.
Nakaoka, Takayoshi; Kaneko, Ken-Ichi; Irie, Satsuki; Mawatari, Aya; Igesaka, Ami; Uetake, Yuta; Ochiai, Hidenori; Niwa, Takashi; Yamano, Emi; Wada, Yasuhiro; Tanaka, Masaaki; Kotani, Kohei; Kawahata, Hideki; Kawabe, Joji; Miki, Yukio; Doi, Hisashi; Hosoya, Takamitsu; Kazuya, Maeda; Kusuhara, Hiroyuki; Sugiyama, Yuichi; Watanabe, Yasuyoshi.
Affiliation
  • Nakaoka T; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Kaneko KI; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Irie S; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Mawatari A; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Igesaka A; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Uetake Y; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Ochiai H; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Niwa T; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Yamano E; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Wada Y; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Tanaka M; Department of Physiology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan.
  • Kotani K; Department of Hepatology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan.
  • Kawahata H; Department of Radiology, Osaka City University Hospital, Abeno-ku, Osaka, 545-8586, Japan.
  • Kawabe J; Department of Nuclear Medicine, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan.
  • Miki Y; Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan.
  • Doi H; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
  • Hosoya T; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; Laboratory of Chemical Bioscience, Institute of Biomaterials a
  • Kazuya M; Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan; Kitasato University School of Pharmacy, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
  • Kusuhara H; Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
  • Sugiyama Y; Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan; Laboratory of Quantitative System Pharmacokinetics / Pharmacodynamics, School of Pharmacy, Josai International University, Kioi-cho, Tokyo, 102-0093, Japan.
  • Watanabe Y; RIKEN Center for Life Science Technologies CLST, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; RIKEN Center for Biosystems Dynamics Research BDR, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. Electronic address: yywata@riken.jp.
Drug Metab Pharmacokinet ; 44: 100449, 2022 Jun.
Article in En | MEDLINE | ID: mdl-35395593
ABSTRACT
It is widely accepted that uptake and efflux transporters on clearance organs play crucial roles in drug disposition. Although in vitro transporter assay system can identify the intrinsic properties of the target transporters, it is not so easy to precisely predict in vivo pharmacokinetic parameters from in vitro data. Positron emission tomography (PET) imaging is a useful tool to directly assess the activity of drug transporters in humans. We recently developed a practical synthetic method for fluorine-18-labeled pitavastatin ([18F]PTV) as a PET probe for quantitative evaluation of hepatobiliary transport. In the present study, we conducted clinical PET imaging with [18F]PTV and compared the pharmacokinetic properties of the probe for healthy subjects with or without rifampicin pretreatment. Rifampicin pretreatment significantly suppressed the hepatic maximum concentration and biliary excretion of the probe to 52% and 34% of the control values, respectively. Rifampicin treatment markedly decreased hepatic uptake clearance (21% of the control), and moderately canalicular efflux clearance with regard to hepatic concentration (52% of the control). These results demonstrate that [18F]PTV is a useful probe for clinical investigation of the activities of hepatobiliary uptake/efflux transporters in humans.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Rifampin Limits: Humans Language: En Journal: Drug Metab Pharmacokinet Journal subject: FARMACOLOGIA / METABOLISMO Year: 2022 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Rifampin Limits: Humans Language: En Journal: Drug Metab Pharmacokinet Journal subject: FARMACOLOGIA / METABOLISMO Year: 2022 Document type: Article Affiliation country: Japan